专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090297509A1 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases 审中-公开
标题翻译：用辐射治疗人类肿瘤和抑制生长因子受体酪氨酸激酶
公开(公告)号：US20090297509A1
公开(公告)日：2009-12-03
申请号：US12321948
申请日：2009-01-26
申请人： Harlan W. Waksal , Mansoor N. Saleh , Francisco Robert , Donald Jay Buchsbaum
发明人： Harlan W. Waksal , Mansoor N. Saleh , Francisco Robert , Donald Jay Buchsbaum
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/2863 , A61K38/00
摘要： A method to inhibit the growth of tumors in human patients, comprising treating the human patients with an effective amount of a combination of radiation and a non-radiolabeled protein receptor tyrosine kinase inhibitor, the overexpression of which can lead to tumorigenesis.
摘要翻译：一种抑制人类患者肿瘤生长的方法，包括用有效量的辐射和非放射性标记的蛋白质受体酪氨酸激酶抑制剂的组合治疗人类患者，其过度表达可导致肿瘤发生。

2. 发明申请

US20090110678A1 RECEPTOR ANTAGONISTS FOR TREATMENT OF METASTATIC BONE CANCER 有权
标题翻译：用于治疗骨癌的受体拮抗剂
公开(公告)号：US20090110678A1
公开(公告)日：2009-04-30
申请号：US11917890
申请日：2006-06-19
申请人： Dale L. Ludwig , Stephen R. Plymate
发明人： Dale L. Ludwig , Stephen R. Plymate
IPC分类号： A61K39/395 , A61P35/00 , A61K31/337 , A61K31/704 , C12N15/13 , C12N15/63 , C12N5/10 , C12N1/19
CPC分类号： A61K38/17 , A61K39/395 , A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/21 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.
摘要翻译：本发明提供了通过施用IGF-1R拮抗剂和/或PDGFRα拮抗剂来治疗骨癌，特别是转移性骨癌的方法。本发明还提供结合人PDGFRα并中和受体活化的抗体。本发明还提供了中和PDGFRα活化的方法，以及使用单独的抗生素或与其它药剂组合治疗具有肿瘤疾病的哺乳动物的方法。

3. 发明授权

US5874542A Single chain antibodies specific to VEGF receptors 失效
标题翻译：对VEGF受体特异性的单链抗体
公开(公告)号：US5874542A
公开(公告)日：1999-02-23
申请号：US866969
申请日：1997-06-02
申请人： Patricia Rockwell , Neil I. Goldstein
发明人： Patricia Rockwell , Neil I. Goldstein
IPC分类号： A61K31/337 , A61K38/00 , A61K39/395 , A61K45/06 , A61K49/00 , A61K51/10 , C07H21/00 , C07K14/485 , C07K14/71 , C07K16/18 , C07K16/22 , C07K16/28 , C12N5/18 , C12N5/20 , C12N15/13 , C12P21/08 , C07K16/00
CPC分类号： A61K31/337 , A61K39/395 , A61K45/06 , C07H21/00 , C07K14/71 , C07K16/22 , C07K16/2863 , A61K2039/505 , A61K38/00 , C07K2317/24 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2319/00
摘要： Monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
摘要翻译：提供了特异性结合VEGF受体的细胞外结构域并中和受体活化的单克隆抗体。还提供了使用这些抗体的体外和体内方法。

4. 发明申请

US20090142358A1 HUMAN ANTIBODIES SPECIFIC TO KDR AND USES THEREOF 有权
标题翻译：人类抗体特异性及其用途
公开(公告)号：US20090142358A1
公开(公告)日：2009-06-04
申请号：US12234203
申请日：2008-09-19
申请人： Zhenping Zhu
发明人： Zhenping Zhu
IPC分类号： A61K39/395 , C12N5/08 , A61P35/00
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.
摘要翻译：本发明提供以与人VEGF相当或高于人VEGF的亲和力结合KDR的抗体，并且中和KDR的活化。抗体包括整个免疫球蛋白，单价Fab和单链抗体，多价单链抗体，双抗体，三抗体和单结构域抗体。本发明还提供编码和表达这些抗体的核酸和宿主细胞。本发明还提供了中和KDR活化的方法，抑制哺乳动物血管发生的方法和抑制哺乳动物肿瘤生长的方法。

5. 发明授权

US07498414B2 Human antibodies specific to KDR and uses thereof 有权
标题翻译：针对KDR的人抗体及其用途
公开(公告)号：US07498414B2
公开(公告)日：2009-03-03
申请号：US10506997
申请日：2003-03-04
申请人： Zhenping Zhu
发明人： Zhenping Zhu
IPC分类号： C07K16/00
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.
摘要翻译：本发明提供以与人VEGF相当或高于人VEGF的亲和力结合KDR的抗体，并且中和KDR的活化。抗体包括整个免疫球蛋白，单价Fab和单链抗体，多价单链抗体，双抗体，三抗体和单结构域抗体。本发明还提供编码和表达这些抗体的核酸和宿主细胞。本发明还提供了中和KDR活化的方法，抑制哺乳动物血管发生的方法和抑制哺乳动物肿瘤生长的方法。

6. 发明授权

US6084060A Composition and method for preserving progenitor cells 失效
标题翻译：用于保存祖细胞的组合物和方法
公开(公告)号：US6084060A
公开(公告)日：2000-07-04
申请号：US825369
申请日：1997-03-28
申请人： Jeffrey G. Moore
发明人： Jeffrey G. Moore
IPC分类号： A61K48/00 , A01N1/02 , A61K35/12 , A61K35/14 , A61K35/28 , A61K38/00 , A61P7/06 , C07K14/415 , C12N5/00
CPC分类号： A01N1/0205 , A01N1/02 , A01N1/0226 , C07K14/415 , A61K38/00
摘要： The invention relates to a protein material which is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The protein has an amino acid sequence comprising AQSLSFSFTKFD (SEQ ID NO:1) and a molecular weight of about 12-20 kD, or has an amino acid sequence comprising VVAVEFD (SEQ ID NO:3) and a molecular weight of about 15-20 kD. Heterodimers of the protein are described, and multimers thereof. Methods of using the protein of the invention for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein. Other therapeutic utilities are also enabled through the invention, for example, expanding progenitor cell populations ex vivo to increase chances of engraftation, improving conditions for transporting and storing progenitor cells, and facilitated gene therapy to treat and cure a broad range of life-threatening hematologic diseases.
摘要翻译：本发明涉及一种有效保留祖细胞的蛋白质材料，例如造血祖细胞。该蛋白质具有包含AQSLSFSFTKFD（SEQ ID NO：1）和约12-20kD的分子量的氨基酸序列，或具有包含VVAVEFD（SEQ ID NO：3）和分子量为约15〜 20 kD。蛋白质的异源二聚体被描述，其多聚体。还描述了使用本发明的蛋白质在体外，离体和体内保存祖细胞的方法。因此，本发明包括诸如用于癌症治疗的骨髓消融治疗的方法，其中通过指定的蛋白质促进骨髓重建。还可通过本发明实现其它治疗用途，例如，离体扩增祖细胞群以增加移植的机会，改善运输和储存祖细胞的条件，以及促进基因治疗治疗和治愈广泛的危及生命的血液学疾病

7. 发明授权

US5501948A Stabilized hepatitis B e antigen suitable for immunoassays 失效
标题翻译：稳定乙型肝炎e抗原适用于免疫测定
公开(公告)号：US5501948A
公开(公告)日：1996-03-26
申请号：US254475
申请日：1994-06-06
申请人： Daniel J. Hicklin , Charles T. Tackney , Harlan W. Waksal
发明人： Daniel J. Hicklin , Charles T. Tackney , Harlan W. Waksal
IPC分类号： C07K14/02 , G01N33/576 , C12Q1/70
CPC分类号： C07K14/005 , G01N33/5762 , C12N2730/10122 , Y10S436/82
摘要： Methods and materials for producing hepatitis virus HBe antigenic proteins useful in immunoassays without the necessity of maintaining these proteins in denaturing environments are disclosed. Assay methods and materials utilizing these HBe proteins are also provided.
摘要翻译：公开了用于免疫测定的肝炎病毒HBe抗原蛋白的生产方法和材料，而不需要在变性环境中维持这些蛋白质。还提供了使用这些HBe蛋白的测定方法和材料。

8. 发明申请

US20090136510A1 Inhibition of macrophage-stimulating protein receptor (RON) and methods of treatment thereof 有权
标题翻译：巨噬细胞刺激蛋白受体（RON）的抑制及其治疗方法
公开(公告)号：US20090136510A1
公开(公告)日：2009-05-28
申请号：US12313589
申请日：2008-11-21
申请人： Daniel Pereira , Jennifer O'Toole
发明人： Daniel Pereira , Jennifer O'Toole
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , C12N15/63 , G01N33/53 , C12N5/00 , C12P21/04
CPC分类号： C07K16/2863 , A61K31/337 , A61K39/39558 , A61K2039/505 , A61K2039/507 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The invention provides antibodies or fragments thereof, including human antibodies, specific for Macrophage-Stimulating Protein Receptor (MSP-R or RON), which inhibit RON activation. Also provided are methods to inhibit RON, particularly the use of RON antibodies to treat diseases such as cancer.
摘要翻译：本发明提供了抑制RON活化的巨噬细胞刺激蛋白受体（MSP-R或RON）特异性的抗体或其片段，包括人抗体。还提供了抑制RON的方法，特别是使用RON抗体治疗诸如癌症的疾病。

9. 发明申请

US20050060779A1 Lectin-derived progenitor cell preservation factors and methods of use 审中-公开
标题翻译：凝集素衍生的祖细胞保存因子及使用方法
公开(公告)号：US20050060779A1
公开(公告)日：2005-03-17
申请号：US10929743
申请日：2004-08-30
申请人： M. Colucci , Maarten Chrispeels , Jeffrey Moore
发明人： M. Colucci , Maarten Chrispeels , Jeffrey Moore
IPC分类号： C12N15/09 , A61K35/12 , C07K14/42 , C12N5/0789 , C12N5/10 , C12N15/90 , A01H5/00 , C07H21/04 , C12N9/24 , C12N5/04
CPC分类号： C12N15/90 , A61K38/00 , A61K2035/124 , C07K14/42 , C12N5/0647 , C12N2501/26 , C12N2501/59
摘要： The invention relates to an isolated nucleic acid molecule that encodes a protein that is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The nucleic acid comprises a sequence defined by SEQ ID NO:1, a homolog thereof, or a fragment thereof. The encoded protein has an amino acid sequence that comprises a sequence defined by SEQ ID NO:2, a homolog thereof or a fragment thereof that contains an amino acid sequence TNNVLQVT. Methods of using the encoded protein for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein. Other therapeutic utilities are also enabled through the invention, for example, expanding progenitor cell populations ex vivo to increase chances of engraftation, improving conditions for transporting and storing progenitor cells, and facilitating gene therapy to treat and cure a broad range of life-threatening hematologic diseases.
摘要翻译：本发明涉及分离的核酸分子，其编码有效保留祖细胞的蛋白质，例如造血祖细胞。核酸包含由SEQ ID NO：1定义的序列，其同系物或其片段。编码的蛋白质具有包含由SEQ ID NO：2定义的序列的氨基酸序列，其含有氨基酸序列TNNVLQVT的同源物或其片段。还描述了使用编码的蛋白质在体外，离体和体内保存祖细胞的方法。因此，本发明包括诸如用于癌症治疗的骨髓消融治疗的方法，其中通过指定的蛋白质促进骨髓重建。通过本发明也可实现其它治疗用途，例如，离体扩增祖细胞群以增加移植的机会，改善运输和储存祖细胞的条件，以及促进基因治疗以治疗和治愈广泛的危及生命的血液学疾病

10. 发明申请

US20040229206A1 Composition and method for preserving progenitor cells 失效
标题翻译：用于保存祖细胞的组合物和方法
公开(公告)号：US20040229206A1
公开(公告)日：2004-11-18
申请号：US10737180
申请日：2003-12-15
申请人： ImClone Systems incorporated
发明人： Jeffrey G. Moore
IPC分类号： A01N001/02 , C07K007/06
CPC分类号： C07K14/415 , A01N1/0226 , A61K38/00
摘要： The invention relates to a protein material which is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The protein has an amino acid sequence comprising AQSLSFSFTKFD (SEQ ID NO:1) and a molecular weight of about 12-20 kD, or has an amino acid sequence comprising VVAVEFD (SEQ ID NO:3) and a molecular weight of about 15-20 kD. Heterodimers of the protein are described, and multimers thereof. Methods of using the protein of the invention for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein. Other therapeutic utilities are also enabled through the invention, for example, expanding progenitor cell populations ex vivo to increase chances of engraftation, improving conditions for transporting and storing progenitor cells, and facilitated gene therapy to treat and cure a broad range of life-threatening hematologic diseases.
摘要翻译：本发明涉及一种有效保留祖细胞的蛋白质材料，例如造血祖细胞。该蛋白质具有包含AQSLSFSFTKFD（SEQ ID NO：1）和约12-20kD的分子量的氨基酸序列，或具有包含VVAVEFD（SEQ ID NO：3）和分子量为约15〜 20 kD。蛋白质的异源二聚体被描述，其多聚体。还描述了使用本发明的蛋白质在体外，离体和体内保存祖细胞的方法。因此，本发明包括诸如用于癌症治疗的骨髓消融治疗的方法，其中通过指定的蛋白质促进骨髓重建。还可通过本发明实现其它治疗用途，例如，离体扩增祖细胞群以增加移植的机会，改善运输和储存祖细胞的条件，以及促进基因治疗治疗和治愈广泛的危及生命的血液学疾病

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式